SEC Form 4 · accession 0001209191-17-020645
Eiger BioPharmaceuticals, Inc. · EIGR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David A Cory
Officer — President and CEO · Director
Period of report
Mar 9, 2017
Accepted (ET)
Mar 14, 2017 · 7:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001305253
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $11.75 | Mar 9, 2017 | A | 133,000 | A | — | Mar 9, 2027 | Common Stock | 133,000 | 133,000 | D |
Explanation of responses
- F1The option vests in equal monthly installments over 48 months measured from March 9, 2017 subject to Reporting Person's continuous service status as of each such date.